What is the purspose of pharmaceutical patents if their application and use oppose what they are supposed to answer in theory? If the risks they claim to reward are very often assumed by massive public investment?
It is this question that Pauline Londeix, co-founder OTMeds (French drug transparency observatory) and co-author of Combien Coûtent Nos Vies (How Much Our Lives Cost editions 10/18, 2022, with Jérome Martin) will debate on october 16, at 8:05 p.m., on ARTE, in the program “27” presented by Nora Hamadi, alongside: Thomas Klit Christensen, Senior Legal Adviser and Head of Foreign Trade Policy at the Danish Pharmaceutical Industry Association (Lif), and Sabine Volger, Health Economist, researcher in pharmaceutical policy at the Gesundheit Österreich GmbH (GÖG Austrian Institute of Public Health) and collaborator with the WHO for pharmaceutical pricing and reimbursement policies.

Date: Sunday October 16, at 8:05 p.m (Paris/Berlin).
On ARTE, for the special broadcast of « 27 »